-

12:28:31 PM

NVAX Stock News

NVAX - Novavax, Inc.

01/19/22 6:21 PM

Nasdaq : NVAX

covid-19

Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Australia's Therapeutic Goods Administration (TGA) has granted approval

RHEA-AI

positive

01/12/22 6:00 AM

Nasdaq : NVAX

covid-19

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today

RHEA-AI

negative

01/10/22 8:39 AM

Nasdaq : NVAX

covid-19

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax' COVID-19 Vaccine in South Africa

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine

RHEA-AI

negative

01/04/22 4:02 PM

Nasdaq : NVAX

conferences

Novavax to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the virtual 40 th Annual J.P. Morgan Healthcare

RHEA-AI

neutral

12/31/21 12:15 PM

Nasdaq : NVAX

covid-19

Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has completed submission of the final data package, including the

RHEA-AI

neutral

12/28/21 9:29 AM

Nasdaq : NVAX

covid-19

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine

RHEA-AI

very positive

12/23/21 6:30 PM

Nasdaq : NVAX

Novavax and SK bioscience Expand Manufacturing Agreement

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today

RHEA-AI

positive

12/22/21 4:02 PM

Nasdaq : NVAX

covid-19

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants- Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise

RHEA-AI

neutral

12/21/21 5:01 PM

Nasdaq : NVAX

clinical trialcovid-19

Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the first booster doses of NVX-CoV2373, the company's recombinant

RHEA-AI

neutral

12/21/21 4:44 PM

Nasdaq : NVAX

covid-19

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine

- WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older- SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons- Recommendation follows grant of WHO

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

NVAX Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.novavax.com
CeoStanley Erck
Security nameNovavax, Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees375
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address21 Firstfield Rd
StateMaryland
CityGaithersburg
Zip20878-1757
CountryUS
Phone12402682000

NVAX Description:

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.